"Proline" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.
| Descriptor ID |
D011392
|
| MeSH Number(s) |
D12.125.072.401.623
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Proline".
Below are MeSH descriptors whose meaning is more specific than "Proline".
This graph shows the total number of publications written about "Proline" by people in this website by year, and whether "Proline" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 3 | 3 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 3 | 4 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 2 | 4 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2010 | 2 | 3 | 5 |
| 2011 | 2 | 2 | 4 |
| 2012 | 2 | 1 | 3 |
| 2013 | 3 | 2 | 5 |
| 2014 | 2 | 4 | 6 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 3 | 4 |
| 2018 | 1 | 2 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 1 |
| 2026 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proline" by people in Profiles.
-
Clostridioides difficile colonization is not mediated by bile salts and utilizes Stickland fermentation of proline in an in vitro model. mSphere. 2025 02 25; 10(2):e0104924.
-
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. Sci Adv. 2023 03 29; 9(13):eade8778.
-
C9orf72 Dipeptide Repeats Cause Selective Neurodegeneration and Cell-Autonomous Excitotoxicity in Drosophila Glutamatergic Neurons. J Neurosci. 2018 08 29; 38(35):7741-7752.
-
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. N Engl J Med. 2017 10 12; 377(15):1448-1455.
-
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. J Hepatol. 2014 Aug; 61(2):200-9.
-
An overview of emerging therapies for the treatment of chronic hepatitis C. Med Clin North Am. 2014 Jan; 98(1):17-38.
-
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. J Hepatol. 2014 Apr; 60(4):748-56.
-
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar; 38(3):316-22.
-
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Liver Int. 2014 May; 34(5):707-19.
-
Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells. Laryngoscope. 2013 Jun; 123(6):1416-23.